BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 36052088)

  • 21. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 22. Development of ductal carcinoma of the pancreas during follow-up of branch duct intraductal papillary mucinous neoplasm of the pancreas.
    Uehara H; Nakaizumi A; Ishikawa O; Iishi H; Tatsumi K; Takakura R; Ishida T; Takano Y; Tanaka S; Takenaka A
    Gut; 2008 Nov; 57(11):1561-5. PubMed ID: 18477671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does a family history of pancreatic ductal adenocarcinoma and cyst size influence the follow-up strategy for intraductal papillary mucinous neoplasms of the pancreas?
    Mandai K; Uno K; Yasuda K
    Pancreas; 2014 Aug; 43(6):917-21. PubMed ID: 24743378
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intraductal papillary mucinous neoplasms of the pancreas with distinct pancreatic ductal adenocarcinomas are frequently of gastric subtype.
    Ideno N; Ohtsuka T; Kono H; Fujiwara K; Oda Y; Aishima S; Ito T; Ishigami K; Tokunaga S; Ohuchida K; Takahata S; Nakamura M; Mizumoto K; Tanaka M
    Ann Surg; 2013 Jul; 258(1):141-51. PubMed ID: 23532108
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cytopathologic diagnosis of oncocytic type intraductal papillary mucinous neoplasm: Criteria and clinical implications of accurate diagnosis.
    Reid MD; Stallworth CR; Lewis MM; Akkas G; Memis B; Basturk O; Adsay V
    Cancer Cytopathol; 2016 Feb; 124(2):122-34. PubMed ID: 26415076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association between hyperechogenic pancreas and pancreatic ductal adenocarcinoma concomitant with intraductal papillary mucinous neoplasms.
    Mandai K; Uno K; Nakase K; Kawamura T; Yasuda K
    J Med Ultrason (2001); 2019 Oct; 46(4):435-439. PubMed ID: 31069577
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary mucinous neoplasms of the pancreas.
    Mito K; Saito M; Morita K; Maetani I; Sata N; Mieno M; Fukushima N
    Pancreatology; 2018 Jun; 18(4):407-412. PubMed ID: 29650332
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The efficacy of adjuvant therapy for pancreatic invasive intraductal papillary mucinous neoplasm (IPMN).
    McMillan MT; Lewis RS; Drebin JA; Teitelbaum UR; Lee MK; Roses RE; Fraker DL; Vollmer CM
    Cancer; 2016 Feb; 122(4):521-33. PubMed ID: 26587698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The application of single-cell sequencing in pancreatic neoplasm: analysis, diagnosis and treatment.
    Lv G; Zhang L; Gao L; Cui J; Liu Z; Sun B; Wang G; Tang Q
    Br J Cancer; 2023 Jan; 128(2):206-218. PubMed ID: 36307645
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular mechanism of intraductal papillary mucinous neoplasm and intraductal papillary mucinous neoplasm-derived pancreatic ductal adenocarcinoma.
    Fukuda A
    J Hepatobiliary Pancreat Sci; 2015 Jul; 22(7):519-23. PubMed ID: 25900667
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deep sequencing of cancer-related genes revealed GNAS mutations to be associated with intraductal papillary mucinous neoplasms and its main pancreatic duct dilation.
    Takano S; Fukasawa M; Maekawa S; Kadokura M; Miura M; Shindo H; Takahashi E; Sato T; Enomoto N
    PLoS One; 2014; 9(6):e98718. PubMed ID: 24897499
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Invasive carcinoma arising in intraductal papillary mucinous neoplasms of the pancreas: a matched control study with conventional pancreatic ductal adenocarcinoma.
    Yopp AC; Katabi N; Janakos M; Klimstra DS; D'Angelica MI; DeMatteo RP; Fong Y; Brennan MF; Jarnagin WR; Allen PJ
    Ann Surg; 2011 May; 253(5):968-74. PubMed ID: 21422912
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Concomitant Intraductal Papillary Mucinous Neoplasm in Pancreatic Ductal Adenocarcinoma Is an Independent Predictive Factor for the Occurrence of New Cancer in the Remnant Pancreas.
    Matsuda R; Miyasaka Y; Ohishi Y; Yamamoto T; Saeki K; Mochidome N; Abe A; Ozono K; Shindo K; Ohtsuka T; Kikutake C; Nakamura M; Oda Y
    Ann Surg; 2020 May; 271(5):941-948. PubMed ID: 30308608
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Malignant potential of intraductal papillary mucinous neoplasms of the pancreas.
    Nakajima Y; Yamada T; Sho M
    Surg Today; 2010 Sep; 40(9):816-24. PubMed ID: 20740343
    [TBL] [Abstract][Full Text] [Related]  

  • 35. GNAS mutation is a frequent event in pancreatic intraductal papillary mucinous neoplasms and associated adenocarcinomas.
    Hosoda W; Sasaki E; Murakami Y; Yamao K; Shimizu Y; Yatabe Y
    Virchows Arch; 2015 Jun; 466(6):665-74. PubMed ID: 25796395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.
    Pea A; Yu J; Rezaee N; Luchini C; He J; Dal Molin M; Griffin JF; Fedor H; Fesharakizadeh S; Salvia R; Weiss MJ; Bassi C; Cameron JL; Zheng L; Scarpa A; Hruban RH; Lennon AM; Goggins M; Wolfgang CL; Wood LD
    Ann Surg; 2017 Jul; 266(1):133-141. PubMed ID: 27433916
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of spatio-temporal recurrence pattern on overall survival for invasive intraductal papillary mucinous neoplasia - A comparison with pancreatic ductal adenocarcinoma.
    Holmberg M; Linder S; Kordes M; Liljefors M; Ghorbani P; Löhr JM; Sparrelid E
    Pancreatology; 2022 Jun; 22(5):598-607. PubMed ID: 35501218
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Digital next-generation sequencing identifies low-abundance mutations in pancreatic juice samples collected from the duodenum of patients with pancreatic cancer and intraductal papillary mucinous neoplasms.
    Yu J; Sadakari Y; Shindo K; Suenaga M; Brant A; Almario JAN; Borges M; Barkley T; Fesharakizadeh S; Ford M; Hruban RH; Shin EJ; Lennon AM; Canto MI; Goggins M
    Gut; 2017 Sep; 66(9):1677-1687. PubMed ID: 27432539
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pancreatic tumor: progress in diagnosis and treatment. Topics: II. Intraductal papillary mucinous neoplasm of the pancreas (IPMN)/mucinous cystic neoplasm (MCN); 2. Pathology and pathobiology].
    Furukawa T; Kuboki Y; Hatori T; Yamamoto M; Shibata N; Shiratori K
    Nihon Naika Gakkai Zasshi; 2012 Jan; 101(1):57-63. PubMed ID: 22413462
    [No Abstract]   [Full Text] [Related]  

  • 40. GNAS and KRAS Mutations Define Separate Progression Pathways in Intraductal Papillary Mucinous Neoplasm-Associated Carcinoma.
    Tan MC; Basturk O; Brannon AR; Bhanot U; Scott SN; Bouvier N; LaFemina J; Jarnagin WR; Berger MF; Klimstra D; Allen PJ
    J Am Coll Surg; 2015 May; 220(5):845-854.e1. PubMed ID: 25840541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.